Form 8-K - Current report:
SEC Accession No. 0001104659-20-102834
Filing Date
2020-09-08
Accepted
2020-09-08 07:53:53
Documents
14
Period of Report
2020-09-08
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2030354d1_8k.htm   iXBRL 8-K 25821
2 EXHIBIT 99.1 tm2030354d1_ex99-1.htm EX-99.1 10969
6 GRAPHIC image_002.jpg GRAPHIC 11510
  Complete submission text file 0001104659-20-102834.txt   231097

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA plx-20200908.xsd EX-101.SCH 3183
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE plx-20200908_lab.xml EX-101.LAB 34591
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE plx-20200908_pre.xml EX-101.PRE 22709
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2030354d1_8k_htm.xml XML 3602
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 201162984
SIC: 2836 Biological Products, (No Diagnostic Substances)